INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disease of the kidney. It affects all races, with an estimated frequency of 1 in 400 to 1 in 1000 live births.¹ It is a systemic disease characterized by multiple bilateral renal cysts, resulting in massive kidney enlargement and progressive functional impairment. Usually, only a few renal cysts are detected in most affected individuals before 30 years of age. However, by the 5th decade of life, numerous renal cysts will be found in the majority of patients. The degree of kidney enlargement correlates with complications such as pain, hematuria, hypertension, and renal insufficiency.

PATHOGENESIS
Autosomal dominant polycystic kidney disease is a heterogeneous disease with 2 gene loci, PKD1 on chromosome 16 and PKD2 on chromosome 4. Approximately, 85% of cases are PKD1, while PKD2 accounts for 15% of ADPKDs. PKD1 genotype is associated with the more severe form of the disease. Cyst number, cyst growth, and eventually, renal expansion are more pronounced in this subgroup. Incidence of hypertension and proteinuria are significantly higher among patients with the PKD1 genotype.² These patients reach end-stage renal disease (ESRD) 20 years earlier on average than the PKD2 cases do (age at ESRD, 54.3 years versus 74.0 years for PKD1 and PKD2, respectively).³ It has been shown that the more severe course of the disease in PKD1 patients is associated with more cyst formation at early ages rather than cyst enlargement.⁴ Both polycystin-1 and polycystin-2, encoded by PKD1 and PKD2 genes, are essential for proper differentiation and low-rate proliferation of the tubular epithelial cells.⁵⁷ Impaired function of any of these protein complexes leads to disrupted intracellular signaling, ciliary dysfunction, apoptosis, and excessive fluid secretion into tubuloepithelium-originated cysts.⁸
It has been demonstrated that only 1% of nephrons will develop cysts. Potentially, cysts can arise from all segments of the nephron; however, collecting duct cysts are more predominant. These cysts tend to expand continuously, and ultimately, detach from the parent tubules, yet continue to grow. A large body of evidence indicates that a considerable proportion of cysts form in utero and progressively enlarge from birth to the 6th decade of life. In a longitudinal ultrasonographic study on 182 children between birth and 20 years of age, Fick-Brosnahan and colleagues reported that age-matched children with ADPKD had larger renal volumes compared to healthy controls. In 2002, the same group at the University of Colorado conducted the first sequential quantitative study of total renal volumes in adults with ADPKD. They followed 229 patients aged between 19 to 81 years, over a mean interval of 7.8 years. The mean rate of renal growth documented by ultrasonography was 8.2% per year. Increased renal volume at baseline was significant in this study, as well (mean baseline total renal volume of 1122 mL). In recent years, the Consortium of Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) published the early analysis of their invaluable study. They showed that the total kidney and cyst volumes increased exponentially. Over a span of 3 years, 241 nonazotemic (glomerular filtration rate [GFR], > 60 mL/min/1.73 m²) adult ADPKD patients aged 15 to 49 years old at baseline were followed up prospectively with yearly magnetic resonance imaging (MRI) examinations. At baseline, the mean combined volume of both kidneys was 1060 ± 642 mL with a mean increase of 204 mL per year (5.3% per year). Total cyst volumes were reported to be 540 mL at baseline and increased by a mean of 12.0% per year over a 3-year period. These findings strongly indicate that total renal volume is a harbinger of subsequential renal growth, and ultimately, kidney function impairment. Although PKD1 kidneys had more cysts and were larger than PKD2 kidneys at baseline, the rates of growth were not significantly different (5.68% per year versus 4.82% per year). Thus genotype likely determines the cyst initiation not cyst expansion. In 2009, Kistler and coworkers from Switzerland provided more support for CRISP findings. The results of total kidney and cyst volumes as well as the growth rates in their 6-month MRI study of 100 adult PKD1 patients were remarkably similar to the CRISP study.

CONSEQUENCES OF RENAL ENLARGEMENT

Renin-Angiotensin-Aldosterone System

Activation of renin-angiotensin-aldosterone system (RAAS) in ADPKD has been demonstrated in several studies. On the other hand, angiographic studies have shown that cyst expansion is associated with the compression of the adjacent parenchyma and vasculature. This results in local glomerular ischemia/hypoxia. Graham and associates reported hyperplasia of renin-containing cells along the arterioles and within cyst walls. Moreover, elevated levels of renin have been detected in both renal tissue and cyst fluid of ADPKD kidneys. In 2004, Loghman-Adham and colleagues described an intrarenal role of RAAS in ADPKD by detecting the angiotensinogen, angiotensin-converting enzyme (ACE), angiotensin II type I (AT1) receptor, and angiotensin II within cysts and tubules. The first clinical study that indicated the activation of RAAS in ADPKD resulted from comparing the effect of ACE inhibitor on plasma renin activity (PRA) in hypertensive versus normotensive patients. Plasma rennin activity was significantly higher in the hypertensive group despite treating with ACE inhibitors. This finding has been confirmed by measuring PRA and aldosterone levels in hypertensive ADPKD patients versus patients with essential hypertension who were matched for blood pressure (BP), renal function, age, and sodium intake. The results demonstrated a prominent increase of PRA and aldosterone in the supine and upright positions, as well as after ACE inhibitor administration, in ADPKD patients. Moreover, with ACE inhibitor, hypertensive ADPKD participants exhibited a significant decrease in renal vascular resistance and consequently an increase in renal blood flow compared to essential hypertension patients.

It has been demonstrated that intrarenal as well as circulatory RAAS is highly activated in ADPKD, whereas there is controversy about the importance of the circulating RAAS. Doulton and colleagues showed equivalent activation of RAAS in hypertensive ADPKD and essential hypertension patients with low or high sodium intake and also after administration of ACE inhibitors. Increased PRA and serum aldosterone have been
documented not only in hypertensive ADPKD, but also in normotensive patients with preserved kidney function.\(^3\)

It has been well understood that early activation of RAAS occurs while ADPKD patients are completely asymptomatic, and this will proceed with hypertension. Although hypertension in ADPKD is multifactorial,\(^3\) activation of RAAS plays a major role in its pathogenesis. Hypertension is highly frequent in the ADPKD with substantial contribution to the disease progression and related morbidity and mortality. Approximately, 60% of the patients develop hypertension without any decline in their GFR (> 75 mL/min/1.73 m²).\(^3,4\)

Hypertension

The incidence of hypertension is at a much younger age in ADPKD (32 and 34 years of age for men and women, respectively). Hypertension occurs even earlier in ADPKD patients with affected hypertensive parents.\(^3\) As mentioned earlier, activation of RAAS is associated with cyst expansion and renal growth, and therefore, hypertension. This correlation has been strongly confirmed by several studies.\(^1,3,16,39,40\) Recently, Cadnapaphonchai and coworkers, in a 5-year randomized study among 85 ADPKD children, reported a strong relationship between renal volume expansion and BP. The results were significant for more aggressive increase in kidney size in hypertensive children (BP > 95th percentile) than children with borderline hypertension (BP < 95th percentile).\(^18\) This clinical trial validates previous reports, describing renal volume as the most relevant characteristic of disease progression and related cardiac morbidity.\(^44,45\) In Cadnapaphonchai and coworkers’ study, this correlation among ADPKD children was well demonstrated not only in hypertensive participants, but also in patients with borderline hypertension.\(^46\) In 116 ADPKD patients in their early 40s, left ventricular hypertrophy was reported in 46% of male and 37% of female patients.\(^50,51\) Of interest, 23% of these patients were normotensive. Nondipper ADPKD patients, those with a BP that does not decrease at night, exhibited higher left ventricular mass index compared to dippers.\(^52\)

In summary, renal enlargement is associated with RAAS activation, hypertension, and eventually, left ventricular mass index increase.

RENAL VOLUME: A HARBINGER

The development of kidney failure in ADPKD is multifactorial and highly variable. As mentioned previously, genotype (\(\text{PKD1}\) versus \(\text{PKD2}\)), site of mutation in \(\text{PKD1}\) gene and modifier genes have significant impact on the clinical course of the disease.\(^53\) According to several cross-sectional and longitudinal human studies, an inverse correlation between GFR and total renal volume has been well described.\(^1,3,16,39,40\) Participants in the CRISP study who were older than 30 years with a total renal volume above 1500 mL at baseline had a greater GFR decline (4.33 ± 8.07 mL/min per year).\(^12\) These findings demonstrate that not only total renal volume, but also the rate of cyst, and eventually, renal growth, are strongly associated with the decline in GFR.

As a consequence of hyperfiltration and compensation of unaffected nephrons, in the vast majority of patients, and despite an insidious and constant increase in renal volume, kidney function remains preserved until the 4th to 6th decade of life. By the time the GFR starts to decline, the average rate of loss is about 4.4 mL/min/y to 5.9 mL/min/y.\(^54\) Therefore, GFR, or its surrogate serum creatinine, seems to be a poor indicator to estimate how advanced the disease is.

Recently, it has been proposed that renal volume can be used as a predictor of ADPKD progression. For clinicians, incorporating only one measurement of total renal volume by ultrasonography, computed tomography, or MRI will allow them to estimate the patient’s kidney expansion rate and expected volume in the years ahead (Figure 1).\(^1,55\) In most of the patients, the kidneys grow symmetrically;
however, in some rare cases, asymmetric cyst distribution has been described either within or between the kidneys.55 In these cases, although the total renal volume could be the same as those of the kidneys with symmetric cystic pattern, the amount of preserved parenchyma might be different. Thus, the association between GFR and total renal volume might be different from the majority of patients.

Understanding the clinical implication of patients’ renal volume and estimated growth rate is very important to stratify at-risk patients (Figure 2).14,55 The patients with larger kidneys and rapid progression should be monitored more frequently in terms of disease-related complications, especially blood pressure control. On the other hand, measuring total renal volume will provide us with a reliable indicator to evaluate if the renal growth rate is in the expected range or has been accelerated.

PAIN AND HEMATURIA

The most common symptom in ADPKD patients is pain, which can occur acutely or chronically. Approximately, 60% of patients experience pain during the course of the disease.33 Patients may present mainly with lower back pain (71.3%), radiculopathies (29.6%), and abdominal pain (61.4%). Abdominal pain can be described as dull pain, uncomfortable fullness, stabbing pain, and cramping.56 Cyst rupture or hemorrhage, infected cysts, and nephrolithiasis are the most frequent etiologies of acute pain. It has been shown that stone formation is related to higher cyst numbers and also larger cysts. Cyst enlargement with secondary renal collecting duct distortion and consequent urine stasis might be the relevant pathophysiology of this finding.57 Cyst rupture and kidney stones are commonly associated with gross hematuria. Gross hematuria is also highly related to the kidney size and hypertension.58,59 Progressive cyst growth contributes to chronic pain. This is due to the renal capsule stretch, renal pedicle traction, and also partial occlusion of collecting ducts.60,61 Moreover, cyst decompression and volumetric reduction procedures and their resultant pain relief, provide sufficient evidence to establish the relationship between the cysts and pain. However, in about 24 months after these interventions, pain symptoms will reappear in more than 40% of the patients.

DIAGNOSIS

The diagnosis of ADPKD is usually made by the aid of imaging modalities. However, the importance of the patient’s education and awareness of the hereditary basis of the disease is indisputable.
This has led to the formation of better family histories and earlier diagnosis of ADPKD. Considering the availability, cost, and safety, the ultrasonography modality has become the main diagnostic tool in the diagnosis of ADPKD. Cysts larger than 10 mm can reliably be detected by ultrasonography. According to the recently revised Ravine’s criteria for diagnosis of ADPKD by ultrasonography, presence of at least 3 renal cysts (unilateral or bilateral) is sufficient for diagnosis of at-risk individuals aged 15 to 39 years old (Table). For at-risk individuals aged 40 to 59 years old and 60 years and older, respectively, 2 and 4 cysts in each kidney are diagnostic. Although the positive predictive value of these criteria is 100%, their sensitivity and negative predictive value for PKD2 is low, especially in at-risk individuals younger than 15 years old (about 67%). However, in at-risk individuals with unknown family genotype, the absence of any renal cyst via ultrasonography associates with a negative predictive value of 100%. Normal kidneys or one renal cyst in individuals older than 40 years old is definitive for disease exclusion. While the Ravine’s criteria focus on at-risk individuals older than 15 years, recently, Reed and colleagues at the University of Colorado evaluated 420 children aged 15 years or younger with a positive family history. They reported bilateral renal cysts found on ultrasonography in 71.5% (181 of 253) of children who had repeated evaluation before 15 years. Of interest, 65% (17 of 26) of children who originally had unilateral cysts developed bilateral cysts on follow-up at the age of 15 or younger. Acknowledging that unilateral cysts might be the only early manifestation of ADPKD in children younger than 15 years, this study supports precise family history taking and further MRI studies to differentiate ADPKD from the entity termed unilateral renal cystic disease. In cases of uncertainty, especially in organ donor individuals with a positive family history of ADPKD, more expensive modalities such as MRI or computed tomography would be the preferred techniques. These highly sensitive methods will enable the detection of even very small cysts (2 mm). Although it has been suggested that ultrasonography provides merely the same sensitivity as MRI in children, incapability to detect short-term prognosis of the disease is of another limitation of ultrasonography. In contrast, MRI has been shown to be more precise and reliable to evaluate total renal and cyst volumes as well as cystic changes over a short-term period. Reed and coworkers showed that the MRI without gadolinium to evaluate total kidney and cyst volumes has the same accuracy as the contrast-enhanced method used in the CRISP study. This is a promising finding in reducing the cost of imaging and prevents the potential risk of developing contrast-induced nephropathy, especially in patients with advanced disease.

With all the advances in imaging techniques, the current available methods to measure kidney and cyst volumes are manual, reader dependent, and time consuming. Developing precise, reproducible, practical, semi or full automatic modalities is highly essential. In addition to imaging studies, genetic testing can always be used in equivocal or indefinite cases. Prenatal and preimplantation genetic testing are rarely considered for ADPKD. Genetic testing can be done either by linkage or sequence analysis. There are limitations to both techniques. Linkage analysis requires the cooperation of affected family members. PKD1 is a large and complex gene, which makes molecular testing by direct DNA analysis difficult (mutation identification, about 90%). Within families with PKD1 gene, a mutation at the 5’ end correlates with a more severe phenotype, earlier onset of ESRD, and higher risk of cerebral aneurysms. No such genotype-phenotype association has been established for PKD2 mutations. However, since

<table>
<thead>
<tr>
<th>Age, y</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 to 29</td>
</tr>
<tr>
<td>30 to 39</td>
</tr>
<tr>
<td>40 to 59</td>
</tr>
<tr>
<td>≥ 60</td>
</tr>
<tr>
<td>Original Ravine’s PKD1 Diagnostic Criteria</td>
</tr>
<tr>
<td>≥ 2 cysts, unilateral or bilateral</td>
</tr>
<tr>
<td>≥ 2 cysts in each kidney</td>
</tr>
<tr>
<td>≥ 4 cysts in each kidney</td>
</tr>
<tr>
<td>Revised Unified Diagnostic Criteria</td>
</tr>
<tr>
<td>≥ 3 cysts, unilateral or bilateral</td>
</tr>
<tr>
<td>≥ 3 cysts in each kidney</td>
</tr>
<tr>
<td>≥ 4 cysts in each kidney</td>
</tr>
<tr>
<td>Revised Criteria for Exclusion of Diagnosis</td>
</tr>
<tr>
<td>≥ 1 cyst</td>
</tr>
<tr>
<td>≥ 2 cysts</td>
</tr>
<tr>
<td>≥ 4 cysts in each kidney</td>
</tr>
</tbody>
</table>

*Adapted from a study of Pei and colleagues. PKD1 indicates polycystic kidney disease 1.
most of the PKD1 mutations are unique and up to one-third are missense, the pathogenecity of some changes is difficult to describe.\textsuperscript{71,72}

CONCLUSIONS

In summary, renal enlargement is associated with RAAS activation and hypertension with consequent left ventricular hypertrophy, as well as pain and hematuria. Understanding the clinical implication of patients’ renal volume and estimated growth rate is important for risk stratification. Ultrasonography remains a low-cost and reliable means to diagnose APDKD in the proper context. Newly proposed ultrasonographic criteria have been discussed. The more precise imaging modalities such as MRI or computed tomography should supplement ultrasonography in cases of uncertainty.

CONFLICT OF INTEREST

None declared.

REFERENCES


27. Chapman AB, Johnson A, Gabow PA, Schrier RW. The
Renal Volume in Polycystic Kidney Disease—Masoumi et al


45. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-52.


60. Milutinovic J, Fialkow PJ, Agodoa LY, Phillips LA, Rudd...
Renal Volume in Polycystic Kidney Disease—Masoumi et al


Correspondence to:
Robert W Schrier, MD
Department of Medicine, University of Colorado Denver, Division of Renal Diseases and Hypertension
12700 East 19th Ave, Box C281, Research 2, Room 7001, Aurora, CO 80045
USA
Tel: +1 303 724 4837
Fax: +1 303 724 4831
E-mail: robert.schrier@ucdenver.edu

Received July 2010